News Aug 29, 2016 European Society of Cardiology (ESC) Congress Presentation Reveals Results From Pre-Clinical Study Using CardioCell’s Stem Cells for Acute Myocardial Infarction (AMI) ROME, ITALY – EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 – Aug. 29, 2016 – Study sponsor
Read MoreCardioCell Reports Positive Results From the First Phase IIa Clinical Trial Using IV Administration of Stem Cells for Chronic Heart Failure Indications
News Aug 28, 2016 CardioCell Reports Positive Results From the First Phase IIa Clinical Trial Using IV Administration of Stem Cells for Chronic Heart Failure Indications ROME, ITALY – EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 – Aug. 28, 2016 – Study sponsor CardioCell LLC, a
Read MoreEuropean Society of Cardiology (ESC) Congress Poster Session Reveals Results From Pre-Clinical Study Using CardioCell’s Stem Cells for Chronic Ischemic Cardiomyopathy
News Aug 28, 2016 European Society of Cardiology (ESC) Congress Poster Session Reveals Results From Pre-Clinical Study Using CardioCell’s Stem Cells for Chronic Ischemic Cardiomyopathy ROME, ITALY – EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 – Aug. 28, 2016 – Study sponsor
Read MoreThree CardioCell-Sponsored Studies Reveal Results at the European Society of Cardiology (ESC) Congress 2016
News Aug 16, 2016 Three CardioCell-Sponsored Studies Reveal Results at the European Society of Cardiology (ESC) Congress 2016 ROME, ITALY – EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 – Aug. 16, 2016 – CardioCell LLC, a global biotechnology company that uses allogeneic stem cells
Read MoreEuropean Society of Cardiology (ESC) Selects CardioCell’s Heart Failure (HF) Study Results for ESC Congress 2016 Late-Breaking Science Session
News Jun 14, 2016 European Society of Cardiology (ESC) Selects CardioCell’s Heart Failure (HF) Study Results for ESC Congress 2016 Late-Breaking Science Session SAN DIEGO — June 14, 2016 — CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for
Read MoreCardioCell Completes Enrollment for a Phase IIa Clinical Trial Using Its Stem Cells for Participants With Chronic Heart Failure
News Apr 19, 2016 CardioCell Completes Enrollment for a Phase IIa Clinical Trial Using Its Stem Cells for Participants With Chronic Heart Failure SAN DIEGO — April 19, 2016 — CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular
Read MoreCardioCell Expands Chronic Heart Failure Phase IIa Clinical Trial to MedStar Washington Hospital Center
News Mar 22, 2016 CardioCell Expands Chronic Heart Failure Phase IIa Clinical Trial to MedStar Washington Hospital Center WASHINGTON, D.C — March 22, 2016 — CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that uses allogeneic stem cells for cardiovascular indications,
Read MoreCardioCell Appoints Timothy Brown, J.D., as Vice President of Intellectual Property
News Dec 16, 2015 CardioCell Appoints Timothy Brown, J.D., as Vice President of Intellectual Property SAN DIEGO — Dec. 16, 2015 — CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that uses allogeneic stem cells for cardiovascular indications, today welcomes Timothy M.
Read More